Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less.

[1]  J. Tisdale,et al.  Hematopoietic Progenitor Cell Mobilization is More Robust in Healthy African American Compared to Caucasian Donors , 2014 .

[2]  J. Wingard,et al.  Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  B. Shaw,et al.  Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. , 2014, Blood.

[4]  J. Wingard,et al.  Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. , 2013, Blood.

[5]  J. Klein,et al.  Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. , 2009, Blood.

[6]  T. Price,et al.  Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  R. Hartzman,et al.  Donation activities and product integrity in unrelated donor allogeneic hematopoietic transplantation: experience of the National Marrow Donor Program. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  G. Ehninger,et al.  Second donation of granulocyte–colony‐stimulating factor–mobilized peripheral blood progenitor cells: risk factors associated with a low yield of CD34+ cells , 2005, Transfusion.

[9]  T. Panzarella,et al.  An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  N. Schmitz,et al.  Differences between graft product and donor side effects following bone marrow or stem cell donation , 2003, Bone Marrow Transplantation.

[11]  C. Scheid,et al.  Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: first interim report of a prospective German multicenter study , 2002, Annals of Hematology.

[12]  A. Gratwohl,et al.  Repeated peripheral stem cell mobilization in healthy donors: time‐dependent changes in mobilization efficiency , 1999, British journal of haematology.

[13]  P. Anderlini,et al.  Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience , 1999, Transfusion.

[14]  Y. Kodera,et al.  Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors , 1999, Bone Marrow Transplantation.

[15]  G. Ehninger,et al.  Acceptance and feasibility of peripheral stem cell mobilisation compared to bone marrow collection from healthy unrelated donors. , 1998, Bone marrow transplantation.

[16]  D. Stroncek,et al.  Blood counts in healthy donors 1 year after the collection of granulocyte–colony‐stimulating factor‐mobilized progenitor cells and the results of a second mobilization and collection , 1997, Transfusion.

[17]  R. Champlin,et al.  Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections , 1997, British journal of haematology.

[18]  D. Stroncek,et al.  Treatment of normal individuals with granulocyte‐colony‐stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells , 1996, Transfusion.

[19]  P. Anderlini,et al.  Transient neutropenia in normal donors after G‐CSF mobilization and stem cell apheresis , 1996, British journal of haematology.

[20]  D. Stroncek,et al.  Changes in blood counts after the administration of granulocyte‐colony‐ stimulating factor and the collection of peripheral blood stem cells from healthy donors , 1996, Transfusion.

[21]  R. Champlin,et al.  Clinical toxicity and laboratory effects of granulocyte‐colony‐ stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures , 1996, Transfusion.